Vanguard Portfolio Management
OBIO icon

Vanguard Portfolio Management’s Orchestra BioMed OBIO Stock Holding History

Vanguard Portfolio Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
+274,973
New +$1.12M ﹤0.01% 2909

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Vanguard Portfolio Management's OBIO Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Orchestra BioMed (OBIO) in Q2 2026: 274,973 shares worth $1.19M. The stake represents ﹤0.01% of the portfolio and ranks #2909 among its holdings.

76 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Vanguard Portfolio Management held 274,973 shares of Orchestra BioMed worth $1.19M as of Q2 2026.
  • Orchestra BioMed was a new Vanguard Portfolio Management position in Q2 2026.
  • Orchestra BioMed made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2909 holding.
  • 76 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.